Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    cp12-0919
Show Display Options
Rank Status Study
1 Active, not recruiting A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Patients With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib
Condition: Hepatocellular Carcinoma
Interventions: Biological: Placebo;   Biological: Ramucirumab DP (IMC-1121B)

Indicates status has not been verified in more than two years